P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Avery Kiejda, Kelly A ^a   Bowden, Nikola A ^b   Croft, Amanda J ^a   Scurr, Lyndee L ^c   Kairupan, Carla F ^b   Ashton, Katie A ^b   Talseth Palmer, Bente A ^b   Rizos, Helen ^c   Zhang, Xu D ^a   Scott, Rodney J ^b   Hersey, Peter ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE NUMBER; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC DIFFERENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; NUCLEOTIDE SEQUENCE; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; WILD TYPE; AGED; CELL CYCLE; DRUG ANTAGONISM; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

ADULT; AGED; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957471582     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-203     Document Type: Article

References (58)

1. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151. 10.1038/sj.onc.1206454, 12789290.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005, 365:687-701.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012. 10.1056/NEJMra041245, 15342808.
4. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1:233-240. 10.1038/35106009, 11902578.
5. Li W, Sanki A, Karim RZ, Thompson JF, Soon Lee C, Zhuang L, McCarthy SW, Scolyer RA. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006, 38:287-301. 10.1080/00313020600817951, 16916716.
6. Gwosdz C, Scheckenbach K, Lieven O, Reifenberger J, Knopf A, Bier H, Balz V. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer 2006, 118:577-582. 10.1002/ijc.21366, 16094622.
7. Soto JL, Cabrera CM, Serrano S, Lopez-Nevot MA. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 2005, 5:36. 10.1186/1471-2407-5-36, 1097717, 15819981.
8. Zerp SF, van Elsas A, Peltenburg LT, Schrier PI. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br J Cancer 1999, 79:921-926. 10.1038/sj.bjc.6690147, 2362648, 10070891.
9. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995, 5:93-100. 10.1097/00008390-199504000-00004, 7620345.
10. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ 2007, 14:3-9. 10.1038/sj.cdd.4402058, 17068503.
11. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604. 10.1038/nrc864, 12154352.
12. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 2006, 13:951-961. 10.1038/sj.cdd.4401916, 16575405.
13. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005, 331:851-858. 10.1016/j.bbrc.2005.03.189, 15865941.
14. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006, 124:207-219. 10.1016/j.cell.2005.10.043, 16413492.
15. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ, Wheeler R, Wong B, Drenkow J, Yamanaka M, Patel S, Brubaker S, Tammana H, Helt G, Struhl K, Gingeras TR. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004, 116:499-509. 10.1016/S0092-8674(04)00127-8, 14980218.
16. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP, Hersey P. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA damaging agent cisplatin. Clin Cancer Res 2008, 14:1659-1668. 10.1158/1078-0432.CCR-07-1422, 18310316.
17. Kichina JV, Rauth S, Das Gupta TK, Gudkov AV. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene 2003, 22:4911-4917. 10.1038/sj.onc.1206741, 12894234.
18. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M, Halazonetis TD. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 2000, 11:467-474.
19. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C, Osman I. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 2002, 94:1803-1806.
20. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 2007, 120:2110-2118. 10.1002/ijc.22512, 17266041.
21. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999, 59:2747-2753.
22. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553. 10.1126/science.1068999, 11910072.
23. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998, 72:8463-8471. 110254, 9765382.
24. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 2000, 7:910-913. 10.1038/sj.gt.3301188, 10849549.
25. SOURCE. , http://smd.stanford.edu/cgi-bin/source/sourceSearch
26. PANTHER Classification system. , http://www.pantherdb.org
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
28. Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer 2007, 97:1225-1233. 10.1038/sj.bjc.6604017, 2360470, 17968428.
29. Chijiwa T, Abe Y, Ikoma N, Yamazaki H, Tsukamoto H, Suemizu H, Kawai K, Wakui M, Nishime C, Matsumoto H, Matsuyama M, Mukai M, Ueyama Y, Nakamura M. Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/gammaCnull (NOG) mice. Int J Oncol 2009, 34:5-13.
30. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994, 59:191-195. 10.1002/ijc.2910590209, 7927918.
31. Ren T, Chen Q, Tian Z, Wei H. Down-regulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice. Biochem Biophys Res Commun 2007, 364:978-984. 10.1016/j.bbrc.2007.10.124, 17971299.
32. Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF. p53 Prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 2010, 23:781-794. 10.1111/j.1755-148X.2010.00773.x, 20849464.
33. Hashimoto Y, Zhang C, Kawauchi J, Imoto I, Adachi MT, Inazawa J, Amagasa T, Hai T, Kitajima S. An alternatively spliced isoform of transcriptional repressor ATF3 and its induction by stress stimuli. Nucleic Acids Res 2002, 30:2398-2406. 10.1093/nar/30.11.2398, 117192, 12034827.
34. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol 2009, 174:2367-2377. 10.2353/ajpath.2009.081057, 2684200, 19389934.
35. Foray N, Marot D, Gabriel A, Randrianarison V, Carr AM, Perricaudet M, Ashworth A, Jeggo P. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. Embo J 2003, 22:2860-2871. 10.1093/emboj/cdg274, 156770, 12773400.
36. Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, McArthur GA, Khanna KK. BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem 2004, 279:31251-31258. 10.1074/jbc.M405372200, 15159397.
37. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 2007, 6:1006-1010. 10.4161/cc.6.9.4211, 17457049.
38. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908. 10.1038/sj.onc.1208615, 15838523.
39. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003, 22:3092-3098. 10.1038/sj.onc.1206461, 12789286.
40. Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007, 13:5991-5994. 10.1158/1078-0432.CCR-07-0686, 17947459.
41. Raj D, Liu T, Samadashwily G, Li F, Grossman D. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 2008, 29:194-201. 2292458, 17916908.
42. Ferguson B, Konrad Muller H, Handoko HY, Khosrotehrani K, Beermann F, Hacker E, Peter Soyer H, Bosenberg M, Walker GJ. Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis. Pigment Cell Melanoma Res 2010, 23:771-780. 10.1111/j.1755-148X.2010.00752.x, 20718941.
43. Vousden KH. Outcomes of p53 activation--spoilt for choice. J Cell Sci 2006, 119:5015-5020. 10.1242/jcs.03293, 17158908.
44. Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008, 15:959-976. 10.1038/cdd.2008.33, 18356920.
45. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79. 10.1038/nm0196-72, 8564846.
46. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999, 104:263-269. 10.1172/JCI6863, 408422, 10430607.
47. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996, 56:892-898.
48. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55:1649-1654.
49. Chaturvedi V, Bodner B, Qin JZ, Nickoloff BJ. Knock down of p53 levels in human keratinocytes increases susceptibility to type I and type II interferon-induced apoptosis mediated by a TRAIL dependent pathway. J Dermatol Sci 2006, 41:31-41. 10.1016/j.jdermsci.2005.10.003, 16289694.
50. Chaturvedi V, Sitailo LA, Qin JZ, Bodner B, Denning MF, Curry J, Zhang W, Brash D, Nickoloff BJ. Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis. Oncogene 2005, 24:5299-5312. 10.1038/sj.onc.1208650, 15940268.
51. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11:1306-1313. 10.1038/nm1320, 2637821, 16286925.
52. Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, Look AT. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005, 123:641-653. 10.1016/j.cell.2005.09.029, 16286009.
53. Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005, 65:2260-2268. 10.1158/0008-5472.CAN-04-3045, 15781639.
54. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, Ji H, Vojtesek B, Bourdon JC, Lane DP, Harris CC. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009, 11:1135-1142. 10.1038/ncb1928, 2802853, 19701195.
55. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004, 4:793-805. 10.1038/nrc1455, 15510160.
56. Minamoto T, Buschmann T, Habelhah H, Matusevich E, Tahara H, Boerresen-Dale AL, Harris C, Sidransky D, Ronai Z. Distinct pattern of p53 phosphorylation in human tumors. Oncogene 2001, 20:3341-3347. 10.1038/sj.onc.1204458, 11423984.
57. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632. 10.1038/nature05287, 17108971.
58. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007, 12:414-418. 10.1016/j.ccr.2007.10.028, 17996645.